Lupin is currently trading at Rs. 1469.90, up by 6.10 points or 0.42% from its previous closing of Rs. 1463.80 on the BSE.
The scrip opened at Rs. 1464.00 and has touched a high and low of Rs. 1477.50 and Rs. 1461.25 respectively. So far 35,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1874.30 on 14-Mar-2016 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.
Last one week high and low of the scrip stood at Rs. 1477.50 and Rs. 1446.45 respectively. The current market cap of the company is Rs. 66,347.00 crore.
The promoters holding in the company stood at 46.71%, while Institutions and Non-Institutions held 41.46% and 11.83% respectively.
Lupin has received final approval for its Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution, 17.5 g/3.13 g/1.6 g per 6 ounces from the United States Food and Drug Administration (USFDA) to market a generic version of Braintree Laboratories’ Suprep Bowel Prep Kit. The company shall commence promoting the product shortly. Suprep Bowel Prep Kit had US sales of $207.2 million, as per IMS MAT December 2016.
Lupin’s Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution, 17.5 g/3.13 g/1.6 g per 6 ounces is the AA rated generic equivalent of Braintree Laboratories’ Suprep Bowel Prep Kit. Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate Oral Solution, 17.5 g/3.13 g/1.6 g per 6 ounces is indicated for cleansing of the colon in preparation for colonoscopy in adults.
Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.